Interleukin-11 (IL-11) is a profibrotic ... Findings were replicated in an independent patient cohort (n=186). Primary human hepatocytes exposed to ethanol were studied in vitro. Ethanol-fed wildtype ...

The discovery broadens the known spectrum of this rare disorder, emphasizing the critical role of collaboration with patient ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Interleukin 2 (IL-2) is the only systemic treatment ... disease recurrence has occurred in only 4 patients; the remaining 19 patients all have ongoing responses of between 2 and 18 years.

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

We harvested chronic periapical periodontitis clinical samples from 106 patients, including 50 boys and 56 girls. Age, sex, and the different pathological types of chronic periapical lesions are ...